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Abstract
Background: Matrix metalloproteinases (MMPs) are believed to be involved in the pathogenesis of idiopathic
pulmonary fibrosis (IPF), and MMP-7 has been described as a useful biomarker for IPF. However, little is known
regarding the significance of MMP-10 as a biomarker for IPF.
Methods: This observational cohort study included 57 patients with IPF. Serum MMPs were comprehensively
measured in all patients, and the relationships between these markers and both disease severity and prognosis
were evaluated. Bronchoalveolar lavage fluid (BALF) MMP-7 and -10 levels were measured in 19 patients to
investigate the correlation between these markers and their corresponding serum values. Immunohistochemical
staining for MMP-10 was also performed in IPF lung tissue.
Results: Serum MMP-7 and -10 levels correlated significantly with both the percentage of predicted forced vital
capacity (ρ = −0.31, p = 0.02 and ρ = −0.34, p < 0.01, respectively) and the percentage of predicted diffusing capacity
of the lung for carbon monoxide (ρ = −0.32, p = 0.02 and ρ = −0.43, p < 0.01, respectively). BALF MMP-7 and -10
levels correlated with their corresponding serum concentrations. Only serum MMP-10 predicted clinical
deterioration within 6 months and overall survival. In IPF lungs, the expression of MMP-10 was enhanced and
localized to the alveolar epithelial cells, macrophages, and peripheral bronchiolar epithelial cells.
Conclusions: MMP-10 may be a novel biomarker reflecting both disease severity and prognosis in patients with IPF.
Keywords: Matrix metalloproteinase-10, Idiopathic pulmonary fibrosis, Biomarker
Background
Idiopathic pulmonary fibrosis (IPF) is a progressive fi-
brotic pulmonary disease with a median survival of 3 to
5 years [1]. The clinical course of IPF is variable and un-
predictable [1–3]. Because survival prediction requires
both a large population and a long follow-up period, sur-
rogate endpoints, such as declines in forced vital cap-
acity (FVC) and diffusing capacity of the lung for carbon
monoxide (DLCO), are often used as primary endpoints
in clinical studies instead of survival [4, 5]. Regarding
serum biomarkers, none have been established as a
widespread clinical marker for IPF [6, 7]. However, pre-
vious studies have suggested that biomarkers, such as
Krebs von den lungen-6 [8], surfactant protein-A (SP-A)
[9], CC chemokine ligand 18 [10], and matrix metallo-
proteinase (MMP)-7 [11], may serve as prognostic
biomarkers for IPF.
MMPs have also been evaluated as biomarkers for IPF.
MMPs are a family of proteinases whose active sites
contain zinc. MMPs play a major role in the degradation
and remodeling of the extracellular matrix (ECM), which
consists primarily of glycoproteins, including collagens,
proteoglycans, and fibronectin. MMPs also regulate mul-
tiple functions, such as cell proliferation, adhesion, mi-
gration, differentiation, and apoptosis, and play a pivotal
role in the pathogenesis of IPF [12]. It has been reported
that MMP-1, -2, and -7 are elevated in the serum and
that MMP-3, -8, and -9 are elevated in the bronchoalve-
olar lavage fluid (BALF) in patients with IPF [2, 13, 14].
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MMP-7 is one of the most extensively investigated
MMPs in IPF. MMP-1 and -7 may be diagnostic bio-
markers that distinguish IPF from other chronic lung
diseases such as chronic obstructive pulmonary disease
and sarcoidosis [15]. Previous studies have also demon-
strated that serum MMP-7 correlates with both FVC
and DLCO and is associated with survival in patients
with IPF [11, 15], suggesting that MMP-7 may be a use-
ful biomarker. Recently, however, it has been reported
that not only MMP-7 but also other MMPs may play a
significant role in the pathogenesis of IPF [13, 16].
As is the case with other MMPs, MMP-10 also plays a
significant role in the degradation and remodeling of the
ECM during tissue repair and vascular remodeling
[17, 18], which suggests that MMP-10 is also an IPF
biomarker candidate. However, in previous studies that
screened serum MMPs in IPF, MMP-10 was not in-
cluded in the analyses [11, 15]. Therefore, little is
known regarding the role of MMP-10 in IPF. In the
present study, serum MMPs, including MMP-10, were
comprehensively measured in patients with IPF, and
their relationships with disease severity, short-term




This was an observational cohort study that enrolled 57
consecutive patients with IPF who visited the Department
of Respiratory Medicine at Kyoto University Hospital. The
diagnosis of IPF was made according to the diagnostic cri-
teria for IPF [1]. Patients who had active malignant disease
or whose forced expiratory volume in one second (FEV1)/
FVC was < 70 % were excluded. The day of serum sam-
pling was set as the baseline, and the patients were pro-
spectively evaluated for clinical deterioration every
6 months from the baseline. Fifteen age- and sex-matched
healthy volunteers without lung disease were recruited as
healthy controls. Twenty patients with chronic obstructive
pulmonary disease (COPD) were also recruited as disease
controls. A diagnosis of COPD was made according to the
Global Initiative for Chronic Obstructive Lung Disease
(GOLD) criteria [19]. The present study was approved by
the Ethics Committee of Kyoto University, and informed
consent was obtained from all patients.
Physiological measurements and bronchoalveolar lavage
The pulmonary function test (PFT) [20], the 6-minute
walk test (6MWT) [21], and the arterial blood gas
(ABG) while breathing room air and bronchoalveolar
lavage (BAL) [22, 23] were performed according to
published guidelines.
MMP analysis
Serum and BALF samples were centrifuged immediately
following sampling, and the supernatants were stored at
-80 °C until needed for analysis. Serum MMP-1,-2, -3, -7,
-8, -9, -10, -12, and -13 and BALF MMP-7 and -10 were
analyzed using the Bio-Plex Pro Human MMP Panel (Bio-
Rad Laboratories, Hercules, CA, USA). Serum samples
were quantified according to the manufacturer’s instruc-
tions using the Bio-Plex 200, a multiplex cytokine array
system. BALF samples and their standards were diluted
using bovine serum albumin-phosphate-buffered saline.
Outcome evaluations
The outcome evaluations included clinical deterioration
within 6 months from baseline and overall survival. Clin-
ical deterioration was defined as a composite outcome
consisting of admission due to respiratory failure, death, ≥
10 % decline in the percentage of predicted FVC (%FVC),
or ≥ 15 % decline in the percentage of predicted DLCO
(%DLCO). We analyzed whether MMPs were associated
with clinical deterioration and overall survival in patients
with IPF.
MMP-10 immunostaining
Lung tissue specimens obtained from 4 patients with IPF
were used for immunohistochemical staining, which was
performed on 5-μm paraffin-embedded sections of lung
tissue to identify MMP-10-expressing sites using the
standard streptavidin-biotin-peroxidase complex method.
For antigen retrieval, slides were immersed in citrate buf-
fer and heated in a microwave oven. A rabbit anti-human
MMP-10 antibody (Abcam, Cambridge, MA, USA) was
applied as a primary monoclonal antibody (1:500 dilution).
Positive staining was visualized using 3,3’-Diaminobenzi-
dine. A pathologist evaluated the localization of MMP-10
expression in IPF lung tissue and compared the results
with control lung specimens, which were obtained from
normal areas distant from the lesions caused by surgically
diagnosed organizing pneumonia (OP).
Statistical analyses
Statistical analyses were performed using JMP 10.0 (SAS
Institute Inc., Cary, NC, USA). Comparisons were per-
formed using Fisher’s test, the Mann-Whitney U test, or
the Steel-Dwass test, where appropriate. Correlations be-
tween variables were evaluated using Spearman’s rank
correlation coefficient. A logistic analysis was used to
predict clinical deterioration within 6 months. To iden-
tify the factors predictive of mortality, we used a Cox
proportional hazards model. A receiver operating char-
acteristic (ROC) analysis of serum MMP-10 was per-
formed to determine the threshold for predicting clinical
deterioration. All analyses were considered statistically
significant when p < 0.05.
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Results
Patient characteristics
Fifty-seven patients with IPF were recruited; all patient
characteristics are shown in Table 1. Ten (17.5 %) pa-
tients were diagnosed by histological confirmation of the
usual interstitial pneumonia (UIP) pattern, whereas the
other patients were diagnosed based on a definite UIP
pattern on high-resolution computed tomography. The
mean age of the patients with IPF was 69.4 years, and 51
(89.5 %) patients were male, whereas the mean age of
patients with COPD or healthy controls was 70.8 and
65.9 years, respectively. All but one patient with COPD
(95.0 %) and all healthy controls were male. No signifi-
cant difference was observed in age and gender ratios
between IPF and COPD nor between IPF and healthy
controls (Table 1). All patients with COPD and seven
control subjects (46.7 %) had current or former history
of smoking. Twenty-five (43.9 %) patients underwent
BAL. Three patients had a history of malignant disease:
1 patient had breast cancer, 1 patient had prostate can-
cer, and another patient had colorectal cancer. No pa-
tients suffered disease recurrence over the more than
3 years following their last treatments. Thirteen patients
were treated at baseline with prednisolone, an immuno-
suppressant, or pirfenidone (Additional file 1: Table S1).
Serum and BALF MMPs in IPF
The serum and BALF concentrations are presented in
Table 2. MMP-13 was excluded from the analysis because
its mean concentration was under the limit of determin-
ation in both patient groups and controls. Serum MMP-1
(p < 0.01), MMP-2 (p = 0.03), MMP-7 (p < 0.01), MMP-8
(p = 0.01), MMP-10 (p < 0.01), and MMP-12 (p < 0.01)
concentrations were significantly elevated in patients
with IPF compared with controls, whereas serum
MMP-2 (p < 0.01), MMP-7 (p < 0.01), MMP-9 (p =
0.03), MMP-10 (p < 0.01), MMP-12 (p = 0.01) concen-
trations were significantly elevated in patients with
IPF compared with COPD patients.
Correlation between serum MMPs and disease severity
The correlation between pulmonary function and MMPs
is shown in Table 3. There were significant correlations
between MMP-7 and the PFT indices, including %FVC
and %DLCO (ρ = −0.31, p = 0.02 and ρ = −0.32, p = 0.02,
respectively). There were also significant correlations be-
tween MMP-10 and %FVC and %DLCO (ρ = −0.34, p <
0.01 and ρ = −0.43, p < 0.01, respectively). There were
significant correlations noted between MMP-10 and the
6-minute walk distance (ρ = −0.38, p < 0.01), as well as
between MMP-10 and minimum oxygen saturation
(SpO2) during the 6MWT (ρ = −0.42, p < 0.01). Only
MMP-10 correlated significantly with the partial pres-
sure of oxygen (ρ = −0.32, p = 0.02).
Correlation between serum and BALF MMPs
Based on the MMP results and their relationship with
disease severity, the BALF concentrations of MMP-7
and -10 were measured. Among the 25 patients who
underwent BAL, serum and BALF MMP measure-
ments were simultaneously performed in 19 patients
to investigate potential correlations. Significant corre-
lations were observed between serum and BALF con-
centrations of MMP-7 and MMP-10 (ρ = 0.64, p < 0.01
and ρ = 0.47, p = 0.04, respectively). We also examined
25 BALF samples from the patients who underwent
both BAL and PFT within a 1-month interval. BALF
MMP-10 correlated significantly with %FVC and
Table 1 Patient characteristics
IPF COPD Control p-value p-value p-value
(n = 57) (n = 20) (n = 15) IPF vs. Control IPF vs. COPD COPD vs. Control
Age, years 69.4 ± 8.5 70.8 ± 7.1 65.9 ± 7.9 NS NS NS
Gender, male 51 (89.5) 19 (95.0) 15 (100) NS NS NS
Current or former smoker 53 (93.0) 20 (100) 7 (46.7) <0.001 NS <0.001
Patients who underwent BAL 25 (43.9) – –
Patients who underwent SLB 10 (17.5) – –
FVC, % predicted 84.2 ± 21.3 93.5 ± 20.1 – NS
DLCO, % predicted 43.7 ± 14.2 56.6 ± 17.5 – 0.004
6MWD, m 454 ± 108 – –
Minimum SpO2 during 6MWT, % 85.7 ± 8.4 – –
PaO2 at room air, Torr 82.6 ± 13.1 – –
The data are presented either as the number (%) or mean ± standard deviation
IPF idiopathic pulmonary fibrosis, COPD chronic obstructive pulmonary disease, NS not significant, BAL bronchoalveolar lavage, BALF bronchoalveolar lavage fluid,
SLB surgical lung biopsy, FVC forced vital capacity, DLCO diffusing capacity of the lung for carbon monoxide, 6MWD 6-minute walk distance, SpO2 oxygen saturation,
6MWT 6-minute walk test, PaO2 partial pressure of oxygen
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%DLCO (ρ = −0.46, p = 0.02 and ρ = -0.44, p = 0.03, re-
spectively), whereas BALF MMP-7 correlated signifi-
cantly with only %DLCO (ρ = −0.54, p = < 0.01).
Relationship between MMPs and clinical deterioration
or survival
The median follow-up time from baseline was 459 days
(range, 12–1853 days). Fourteen patients deteriorated clin-
ically within 6 months; 2 died due to an acute exacerba-
tion (AE), and 9 exhibited declines in pulmonary function.
Furthermore, 3 patients were admitted due to respiratory
failure: 2 suffered from chronic respiratory failure, and 1
suffered from a respiratory infection. The causes of death
at more than 6 months following baseline included 3 cases
of AE, 2 cases of chronic respiratory failure, 1 case of
acute lung injury due to pulmonary infection, 1 case of
lung cancer, 1 case of sepsis, and 1 case without a clear
diagnosis. Logistic analyses for clinical deterioration
within 6 months revealed that serum MMP-10 was a sig-
nificant predictor of clinical deterioration, as were %FVC
and %DLCO (Table 4A). A survival analysis performed
using a Cox proportional hazard model demonstrated that
serum MMP-10, as well as %FVC and %DLCO, was a sig-
nificant predictor of mortality among patients with IPF
(Table 4B). Serum MMP-10 was a significant predictor of
clinical deterioration and mortality, even when the pa-
tients treated at baseline were excluded (Additional file 1:
Table S2). In contrast, serum and BALF MMP-7 were not
predictors of either clinical deterioration within 6 months
or mortality.
Table 2 Serum and BALF MMP concentrations
IPF COPD Control p-value p-value p-value
(n = 57) (n = 20) (n = 15) IPF vs. Control IPF vs. COPD COPD vs. Control
Serum
MMP-1, ng/mL 1.52 ± 1.36 0.95 ± 0.74 0.60 ± 0.58 0.005 NS NS
MMP-2, ng/mL 73.5 ± 60.8 27.6 ± 11.8 41.3 ± 40.6 0.034 <0.001 NS
MMP-3, ng/mL 8.43 ± 10.51 4.54 ± 2.26 3.78 ± 3.00 NS NS NS
MMP-7, ng/mL 8.39 ± 4.32 1.72 ± 0.65 2.14 ± 1.41 <0.001 <0.001 NS
MMP-8, ng/mL 1.43 ± 1.50 0.80 ± 0.62 0.47 ± 0.51 0.012 NS NS
MMP-9, ng/mL 38.7 ± 26.8 23.3 ± 15.7 25.9 ± 24.0 NS 0.030 NS
MMP-10, ng/mL 1.18 ± 0.83 0.16 ± 0.18 0.18 ± 0.18 <0.001 <0.001 NS
MMP-12, ng/mL 0.31 ± 0.23 0.17 ± 0.11 <0.1a <0.001 0.013 <0.001
MMP-13, ng/mL <0.1a <0.1a <0.1a
KL-6, U/mL 1084.2 ± 724.4 – –
SP-D, ng/mL 300.4 ± 223.7 – –
BALF
MMP-7, ng/mL 9.6 ± 10.7 – –
MMP-10, ng/mL 0.10 ± 0.09 – –
The data are presented as the mean ± standard deviation
IPF idiopathic pulmonary fibrosis, COPD chronic obstructive pulmonary disease, MMP matrix metalloproteinase, NS not significant, KL-6 Krebs von den lungen-6,
SP-D surfactant protein-D, BALF bronchoalveolar lavage fluid
aThe mean is under the limit of determination
Table 3 Correlations between function measurements and serum matrix metalloproteinases in IPFa
MMP-1 MMP-2 MMP-3 MMP-7 MMP-8 MMP-9 MMP-10 MMP-12
%FVC – – – -0.308* – – -0.344† –
%DLCO – – -0.251 -0.316
* – – −0.434† –
6MWD – −0.355† – – −0.228 – −0.384† −0.309*
Minimum SpO2 during the 6MWT – – −0.235 −0.261 – – −0.416
† –
PaO2 in room air – – – – – – −0.318
* –
The data are shown as Spearman’s ρ when the p-value < 0.10
IPF idiopathic pulmonary fibrosis, MMP matrix metalloproteinase, %FVC percentage of predicted forced vital capacity, %DLCO percentage of predicted diffusing
capacity of the lung for carbon monoxide, 6MWD 6-minute walk distance, SpO2 oxygen saturation, 6MWT 6-minute walk test, PaO2 partial pressure of oxygen
aMMP-13 was excluded from the analysis
*p < 0.05, †p < 0.01
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We performed an ROC analysis to determine the opti-
mal cut-off value of serum MMP-10 for predicting clinical
deterioration. The curve had an AUC of 0.741 and a cut-
off value of 0.986 ng/μL. When 1.0 ng/μL was set as the
threshold, patients with higher values had a significantly
higher frequency of clinical deterioration within 6 months
compared with patients with lowers values (p = 0.01). Fur-
thermore, the mortality of the patients with higher serum
MMP-10 values was significantly higher than patients with
lower values (log rank test; p = 0.049).
Immunohistochemistry
Immunohistochemical staining for MMP-10 was per-
formed in IPF lung tissue. The expression of MMP-10 was
localized primarily to the alveolar macrophages, alveolar
epithelial cells, and peripheral bronchiolar epithelial cells
in IPF lung tissue (Fig. 1). Positive immunostaining
for MMP-10 was observed in both macrophages and
alveolar epithelial cells in control lung tissue. How-
ever, the number of positive cells was reduced, and
the signal intensity was weaker in control lung tissue
compared with IPF lung tissue.
Discussion
In the present study, several MMPs, including MMP-10,
were significantly elevated in the sera of the patients with
IPF compared with the patients with COPD and controls.
MMP-10 and -7 correlated significantly with several
physiological indices, including %FVC and %DLCO. Fur-
thermore, a higher serum MMP-10 level was associated
with both clinical deterioration within 6 months and over-
all survival. In IPF lungs, MMP-10 was expressed in alveo-
lar macrophages and epithelial cells.
MMPs reportedly play an important role in the patho-
genesis of IPF [13]. Previous studies have demonstrated
that both BALF and serum MMP-1 were elevated in IPF
[14, 15]. The biological roles of MMP-1 suggest that it
may play an important role in the pathogenesis of IPF
[13, 24]. MMP-3-knockout mice and MMP-7-knockout
mice do not develop pulmonary fibrosis induced by
bleomycin [25, 26], suggesting that MMP-3 and -7 may
also act as mediators of pulmonary fibrosis. Indeed,
MMP-1 and -7 were also increased in the patients with
IPF compared with controls in the present study.
In previous studies, however, few MMPs reportedly
correlated with disease severity and prognosis despite
their possible roles in the pathogenesis of IPF. Serum
MMP-7 concentrations were elevated in patients with
subclinical interstitial lung disease (ILD) and correlated
negatively with %FVC and %DLCO, whereas no signifi-
cant correlation was noted between serum MMP-1 and
pulmonary function [15]. High levels serum MMP-7 and
SP-A may predict shorter survival in patients with IPF
[27]. In the present study, we demonstrated a correlation
between MMP-7 and pulmonary function, including
%FVC and %DLCO, that was consistent with the findings
of the previous studies. Furthermore, we observed that
serum MMP-10 correlated more significantly with dis-
ease severity and prognosis in patients with IPF
compared with MMP-7.
MMP-10, like MMP-3 and -11, is categorized into stro-
melysins and degrades a variety of ECM proteins, including
proteoglycans, laminin, fibronectin, gelatins, and collagen
types III, IV, V, and IX [18, 28, 29]. MMP-10 activates other
MMPs, including proMMP-1, -7, -8, and -9 [17, 30].
MMP-10 expression is observed in injured and remodeling
tissues as well as in various types of cells, including the ker-
atinocytes present in skin wounds, injured colonic tissue,
and different cells in injured liver [18, 31, 32]. MMP-10 is
one of the most well-known MMPs involved in the
pathogenesis of carcinomas. Elevated levels of MMP-
10 protein have been observed in tumors, including
non-small cell lung cancer [33], head and neck squa-
mous cell carcinoma [34], bladder transitional cell
carcinoma [35], epithelial skin cancer [36], renal cell
carcinoma [37], and colon adenocarcinoma [38].
In experimental models, MMP-10 was elevated via ex-
posure to cerium oxide or silica [39, 40]. A previous
study evaluating the degree of pulmonary fibrosis in-
duced by ultrafine amorphous silica also demonstrated
that the expression of MMP-10 was associated with pul-
monary fibrosis [41]. Transforming growth factor-β
Table 4 Univariate analyses utilized to predict clinical
deterioration and mortality
(A) Logistic regression models utilized to predict clinical deterioration
within 6 months
Odds ratio 95 % CI p-value
%FVC 0.959 0.922–0.992 0.014
%DLCO 0.903 0.824–0.964 <0.001
Serum MMP-7 0.483
Serum MMP-10 2.716 1.184–7.830 0.017
BALF MMP-7 NA
BALF MMP-10 NA
(B) Cox hazard models utilized to predict mortality
Hazard ratio 95 % CI p-value
%FVC 0.952 0.917–0.986 0.005
%DLCO 0.892 0.828–0.950 <0.001
Serum MMP-7 0.595
Serum MMP-10 1.773 1.032–2.887 0.039
BALF MMP-7 0.992
BALF MMP-10 0.377
The odds ratio and hazard ratio are shown when p < 0.10
CI confidence interval, %FVC percentage of predicted forced vital capacity,
%DLCO percentage of predicted diffusing capacity of the lung for carbon
monoxide, MMP matrix metalloproteinase, BALF bronchoalveolar lavage fluid,
NA not available
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(TGF-β) is elevated in IPF and exerts profibrotic effects,
such as fibroblast differentiation, suppression of myofi-
broblast apoptosis, ECM induction, and regulation of
the balance between MMPs and tissue inhibitors of
MMPs [42, 43]. Furthermore, TGF-β up-regulates
several MMPs, including MMP-10, in epithelial cells
[44, 45]. Therefore, pulmonary fibrosis may be induced
by TGF-β through several pathways, including MMP-10.
Taken together, MMP-10 may be involved in the patho-
genesis of pulmonary fibrosis, as with other MMPs, such
as MMP-1 and -7.
We observed that in human fibrotic lungs, the expres-
sion of MMP-10 was localized to the alveolar epithelial
cells, macrophages, and peripheral bronchiolar epithelial
cells. MMP-10 reportedly localized to fibrotic regions
and alveolar macrophages in cerium oxide-treated lungs
and silica-induced pulmonary fibrosis [39, 40]. However,
the localization of MMP-10 has not been investigated in
IPF. Most MMPs, including MMP-1, -2, -7, and -9, are
expressed in alveolar epithelial cells, whereas other
MMPs, including MMP-2 and -9, may be found in the
fibroblastic foci in IPF [2]. Immunohistochemical results
and the significant correlation between serum and BALF
MMP-10 observed in the present study suggest that
serum MMP-10 in IPF is derived from the epithelial cells
and macrophages in the lungs.
Despite a more significant correlation of serum MMP-
10 with disease severity and prognosis compared with
other MMPs, serum concentrations of MMP-10 were
lower than many other MMPs in IPF. Although the rea-
son was unclear, the abundant MMP-10 expression in
IPF lungs visualized by immunological staining and the
significant association between serum MMP-10 and clin-
ical features may suggest that MMP-10 plays a signifi-
cant role in the pathogenesis of IPF.
There were some limitations to the present study. First,
the number of patients was small. Additional prospective
studies with larger numbers of patients are necessary to
validate the role of MMP-10 as a biomarker for IPF. Sec-
ond, we did not investigate MMPs in other ILDs, such as
nonspecific interstitial pneumonia, connective tissue
disease-associated ILD, and OP. MMP-7 is reportedly ele-
vated in other ILDs, such as cryptogenic OP and systemic
sclerosis-associated ILD [46–48]; therefore, the up-
regulation of MMP-10 may not be specific to IPF. Third,
some patients had already been treated with prednisolone,
an immunosuppressant, or pirfenidone at baseline. Pirfe-
nidone, an antifibrotic agent that suppresses TGF-β, may
affect the expression of MMPs, including MMP-10 [49].
However, the prognostic significance of serum MMP-10
persisted after excluding the treated patients.
We concluded that MMP-10 is a novel biomarker for
IPF, correlates with disease severity, and predicts disease
progression. Additional studies are necessary to eluci-
date the functional role of MMP-10 and other MMPs in
the pathogenesis of IPF.
Fig. 1 The immunohistochemical expression of matrix metalloproteinase (MMP)-10 in idiopathic pulmonary fibrosis (IPF) lung tissue and control
lung tissue. (a-c) The expression of MMP-10 is weakly positive in alveolar epithelial cells and macrophages in control lung tissue. (d-f) In IPF lung
tissue, MMP-10 is expressed predominantly in alveolar macrophages, alveolar epithelial cells, and peripheral bronchiolar epithelial cells. The staining
intensity of MMP-10 in IPF lung tissue is stronger compared with control lung tissue
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Additional file
Additional file 1: Table S1. Treatment for IPF at baseline. Table S2.
Univariate analyses utilized to predict clinical deterioration and mortality
when 13 treated patients with IPF were excluded. (DOCX 24 kb)
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